Related Experiment Videos
Acute liver failure in the United States
1Division of Digestive Liver Diseases, University of Texas Southwestern Medical Center Dallas, Texas, USA. William.Lee@utsouthwestern.edu
Seminars in Liver Disease
|October 3, 2003
Summary
Acute liver failure (ALF) is often drug-induced, with acetaminophen being a common cause. Survival rates vary by cause, with over 43% recovering without transplant, but liver support machines have yet to prove effective.
Area of Science:
- Hepatology
- Clinical Medicine
- Toxicology
Background:
- Acute liver failure (ALF) is a critical condition with significant mortality and morbidity.
- Multicenter studies in the US over the past 5 years have improved the definition and understanding of ALF.
- Drug-induced hepatotoxicity is the leading cause of ALF, accounting for over 50% of cases.
Purpose of the Study:
- To define acute liver failure (ALF) in the United States.
- To analyze the causes, outcomes, and potential treatments for ALF.
- To identify areas for future research in ALF management.
Main Methods:
- Analysis of data from a multicenter approach over the last 5 years in the United States.
- Categorization of ALF cases by etiology, including drug-related hepatotoxicity (acetaminophen and idiosyncratic drugs) and unknown causes.
- Evaluation of patient outcomes based on etiology, hepatic encephalopathy, and complications such as infection.
Main Results:
- Drug-related hepatotoxicity is the primary cause of ALF (over 50%), with acetaminophen toxicity (40%) and idiosyncratic drugs (approx. 12%) being significant contributors.
- Approximately 20% of ALF cases remain of unknown etiology.
- Survival rates: 43% survive without transplant, 28% die, and 29% undergo liver transplantation.
- Liver support machines have not demonstrated an impact on ALF outcomes to date.
Conclusions:
- The etiology of ALF significantly influences patient outcomes.
- Infection remains a principal complication affecting ALF prognosis.
- Future research should prioritize reducing drug-induced ALF, investigating unknown etiologies, and developing effective liver support systems.